Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).
Sponsor: Mirum Pharmaceuticals, Inc.
Summary
This study is designed to assess whether the investigational drug maralixibat, is safe and well tolerated in children \<12 months of age with Alagille Syndrome \[ALGS\] or Progressive Familial Intrahepatic Cholestasis \[PFIC\].
Official title: Open-Label, Phase 2 Study to Evaluate the Safety and Tolerability of Maralixibat in the Treatment of Infants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis and Alagille Syndrome
Key Details
Gender
All
Age Range
0 Days - 364 Days
Study Type
INTERVENTIONAL
Enrollment
27
Start Date
2021-09-09
Completion Date
2024-12-17
Last Updated
2026-06-02
Healthy Volunteers
No
Interventions
Maralixibat
Maralixibat chloride provided in the form of an oral solution (i.e., 5, 10, 15, and 20 mg/mL) * 400 μg/kg maralixibat chloride is equivalent to 380 µg/kg maralixibat free base * 600 μg/kg maralixibat chloride is equivalent to 570 µg/kg maralixibat free base
Locations (14)
Children Hospital LA
Los Angeles, California, United States
University of California - San Francisco
San Francisco, California, United States
Medstar Georgetown University Hospital
Washington D.C., District of Columbia, United States
Ochsner Hospital for Children
New Orleans, Louisiana, United States
Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, United States
Texas Children's Hospital
Houston, Texas, United States
Seattle Children's Hospital
Seattle, Washington, United States
Cliniques Universitaires Saint-Luc
Brussels, Belgium
Sociedade Beneficente de Senhoras - Hospital Sírio-Libanês
São Paulo, Brazil
Hôpital Kremlin Bicêtre
Le Kremlin-Bicêtre, France
Hopital Necker
Paris, France
Consultorio de Joshue David Covarrubias Esquer
Zapopan, Mexico
Instytut Pomnik-Centrum Zdrowia Dziecka
Warsaw, Poland
King's College Hospital
London, United Kingdom